semaglutide and cushing's Efficacy safety of GLP-1 receptor agonists in the treatment of type 2 diabetes and/or obesity in patients with syndrome: a multicenter retrospective study | Endocrine Amy Schumer says she wouldn't

Cognitive and Neurological Support Protocols Cognitive and neurological support protocols remain largely experimental with animal research using 10 mg/kg body weight 5x per week for 3 weeks showing cognitive improvements

Weight loss was also observed, with a modest correlation between alcohol reduction and weight change, suggesting GLP-1RAs may simultaneously target both alcohol use and obesity

There is a particular lack of interventional data for patients with advanced CKD and dialysis

You can skip the snacks

According to current guidance: GLP-1 medications are FDA-approved only for adolescents aged 12 and above with severe obesity (defined as a BMI of 120% or more of the 95th percentile)